Lisa A. Jackson, MD, MPH, is an internist and infectious disease epidemiologist who has conducted clinical and epidemiologic studies of vaccine safety and efficacy since 1991.
Dr. Jackson is the principal investigator (PI) of KPWHRI’s Vaccine and Treatment Evaluation Unit — one of 10 network sites that the National Institutes of Health (NIH) sponsors. In this role, she leads the phase 1 clinical trial of the COVID-19 vaccine co-developed by Moderna and NIH. Launched in March 2020, this trial was the first in the world to begin testing a COVID-19 vaccine. She is also leading the phase 3 clinical trials of the COVID-19 vaccines developed by Moderna and NIH and by Janssen Pharmaceutical Companies, part of Johnson & Johnson, at KPWHRI.
Additionally, Dr. Jackson serves as KPWHRI’s principal investigator in the Vaccine Safety Datalink Project (VSDP). Sponsored by the Centers for Disease Control and Prevention (CDC), VSDP conducts ongoing research on the safety of licensed vaccines in routine use.
Dr. Jackson has written more than 200 peer-reviewed publications and 14 book chapters. She is a past member of the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee and the National Vaccine Program Office’s National Vaccine Advisory Committee.
After receiving her medical degree from the University of Virginia School of Medicine, in Charlottesville, Dr. Jackson earned her Master of Public Health (MPH) degree at the University of Washington (UW) School of Public Health. She completed her internal medicine residency training at the UW School of Medicine and served as an epidemic intelligence officer and preventive medicine resident at the CDC.
Vaccine safety; COVID-19 vaccine safety and effectiveness; influenza vaccine effectiveness in the elderly; methodologic issues in vaccine effectiveness evaluations; pneumococcal polysaccharide vaccine effectiveness; pneumococcal conjugate vaccine immunogenicity in the elderly; epidemiology of E. coli bacteremia; epidemiology of community-acquired pneumonia
Irving SA, Crane B, Weintraub E, Kauffman TL, Brooks N, Patel SA, Razzaghi H, Belongia EA, Daley MF, Getahun D, Glenn SC, Hambidge SJ, Jackson LA, Kharbanda E, Klein NP, Zerbo O, Naleway AL. Influenza vaccination among pregnant people before and during the coronavirus disease 2019 (COVID-19) pandemic. Obstet Gynecol. 2023 Sep 1;142(3):636-639. doi: 10.1097/AOG.0000000000005285. Epub 2023 Aug 3. PubMed
Branche AR, Rouphael NG, Diemert DJ, Falsey AR, Losada C, Baden LR, Frey SE, Whitaker JA, Little SJ, Anderson EJ, Walter EB, Novak RM, Rupp R, Jackson LA, Babu TM, Kottkamp AC, Luetkemeyer AF, Immergluck LC, Presti RM, BÃ¤cker M, Winokur PL, Mahgoub +++. Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial. Nat Med. 2023;29(9):2334-2346. doi: 10.1038/s41591-023-02503-4. Epub 2023 Aug 28. PubMed
Kenigsberg TA, Goddard K, Hanson KE, Lewis N, Klein N, Irving SA, Naleway AL, Crane B, Kauffman TL, Xu S, Daley MF, Hurley LP, Kaiser R, Jackson LA, Jazwa A, Weintraub ES. Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines. Vaccine. 2023 Sep 7;41(39):5678-5682. doi: 10.1016/j.vaccine.2023.08.023. Epub 2023 Aug 19. PubMed
Rouphael NG, Branche AR, Diemert DJ, Falsey AR, Losada C, Baden LR, Frey SE, Whitaker JA, Little SJ, Kamidani S, Walter EB, Novak RM, Rupp R, Jackson LA, Babu TM, Kottkamp AC, Luetkemeyer AF, Immergluck LC, Presti RM, Bäcker M, Winokur PL, Mahgoub SM, Goepfert PA, Fusco DN, Atmar RL, Posavad CM, Netzl A, Smith DJ, Telu K, Mu J, McQuarrie LJ, Makowski M, Makhene MK, Crandon S, Montefiori DC, Roberts PC, Beigel JH. Immunogenicity of a two dose regimen of Moderna mRNA Beta/Omicron BA.1 bivalent variant vaccine boost in a randomized clinical trial. J Infect Dis. 2023 Aug 10;jiad323. doi: 10.1093/infdis/jiad323. Online ahead of print. PubMed
Lyke KE, Atmar RL, Dominguez Islas C, Posavad CM, Deming ME, Branche AR, Johnston C, El Sahly HM, Edupuganti S, Mulligan MJ, Jackson LA, Rupp RE, Rostad CA, Coler RN, Bäcker M, Kottkamp AC, Babu TM, Dobrzynski D, Martin JM, Brady RC, Frenck RW Jr, Rajakumar K, Kotloff K, Rouphael N, Szydlo D, PaulChoudhury R, Archer JI, Crandon S, Ingersoll B, Eaton A, Brown ER, McElrath MJ, Neuzil KM, Stephens DS, Post DJ, Lin BC, Serebryannyy L, Beigel JH, Montefiori DC, Roberts PC; DMID 21-0012 Study Group. Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants. NPJ Vaccines. 2023 Jul 11;8(1):98. doi: 10.1038/s41541-023-00693-z. PubMed
Kenigsberg TA, Hanson KE, Klein NP, Zerbo O, Goddard K, Xu S, Yih WK, Irving SA, Hurley LP, Glanz JM, Kaiser R, Jackson LA, Weintraub ES. Safety of simultaneous vaccination with COVID-19 vaccines in the Vaccine Safety Datalink. Vaccine. 2023 Jun 15:S0264-410X(23)00717-X. doi: 10.1016/j.vaccine.2023.06.042. [Epub ahead of print]. PubMed
Greenberg V, Vazquez-Benitez G, Kharbanda EO, Daley MF, Fu Tseng H, Klein NP, Naleway AL, Williams JTB, Donahue J, Jackson L, Weintraub E, Lipkind H, DeSilva MB. Tdap vaccination during pregnancy and risk of chorioamnionitis and related infant outcomes. Vaccine. 2023 May 22; 41(22): 3429-3435. Published online 2023 Apr 26. doi: 10.1016/j.vaccine.2023.04.043. PubMed
Chavtur C, Staubus WJ, Ho M, Hergott DEB, Seilie AM, Healy S, Duffy P, Jackson L, Talley A, Kappe SHI, Hoffman SL, Richie TL, Kublin JG, Chang M, Murphy SC. Plasmodium 18S Ribosomal RNA Biomarker Clearance After Food and Drug Administration-Approved Antimalarial Treatment in Controlled Human Malaria Infection Trials. Open Forum Infect Dis. 2023 Apr 13;10(5):ofad202. doi: 10.1093/ofid/ofad202. eCollection 2023. PubMed
Branche AR, Rouphael NG, Losada C, Baden LR, Anderson EJ, Luetkemeyer AF, Diemert DJ, Winokur PL, Presti RM, Kottkamp AC, Falsey AR, Frey SE, Rupp R, Bäcker M, Novak RM, Walter EB, Jackson LA, Little SJ, Immergluck LC, Mahgoub SM, Whitaker JA, Babu TM, Goepfert PA, Fusco DN, Atmar RL, Posavad CM, Netzl A, Smith DJ, Telu K, Mu J, Makowski M, Makhene MK, Crandon S, Montefiori DC, Roberts PC, Beigel JH. Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 bivalent boosts: Preliminary results from the COVAIL randomized clinical trial. Clin Infect Dis. 2023 Aug 22;77(4):560-564. doi: 10.1093/cid/ciad209. PubMed
Hanson KE, Marin M, Daley MF, Groom HC, Jackson LA, Sy LS, Klein NP, DeSilva MB, Panagiotakopoulos L, Weintraub E, Belongia EA, McLean HQ. Safety of measles, mumps, and rubella vaccine in adolescents and adults in the Vaccine Safety Datalink. Vaccine X. 2023 Feb 4;13:100268. doi: 10.1016/j.jvacx.2023.100268. eCollection 2023 Apr. PubMed
The NIH-sponsored trial will help inform decisions about vaccine approval for 12- to 17-year-olds.
The investigational vaccine is in the third phase of trials and targets flu strains expected to circulate this winter.
KPWHRI researchers analyzed data from more than 640,000 vaccine doses to understand risk of severe reactions.
Encouraging immune-response and safety data emerge from preliminary human test of genetically attenuated parasite vaccine.
Seattle NPR affiliate KUOW-FM, April 8, 2021